← Back to Clinical Trials
Recruiting NCT06871254

NCT06871254 Spinal Cord Injury Neurorecovery Collaboration

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06871254
Status Recruiting
Phase
Sponsor University of Melbourne
Condition Spinal Cord Injuries
Study Type INTERVENTIONAL
Enrollment 24 participants
Start Date 2025-03-01
Primary Completion 2027-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Therapeutic Intermittent Hypoxia (TIH) + Exercise Training (ET)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 24 participants in total. It began in 2025-03-01 with a primary completion date of 2027-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

SCINC is an adaptive design Master protocol that seeks to determine if there is "sufficient promise" of beneficial effect of treatment combinations to enhance motor recovery in pre-specified strata of people with a spinal cord injury.

Eligibility Criteria

SCINC Inclusion Criteria: \- Person with SCI SCINC Exclusion Criteria: \- Proven contraindication to intervention RRULI: Appendix 1 (TIH + ET) study-specific inclusion criteria: * Adults \> 18 years of age * Able to independently ventilate * Chronic SCI (\>1 years post-injury or impairment onset) * Tetraplegia (C2-T1 level of injury) * Evidence of motor incomplete paralysis in the upper limb below the neurological level of injury * Have a documented management plan for their AD if it occurs. RRULI: Appendix 1 (TIH + ET) study-specific exclusion criteria: * Pregnancy * Medical instability, including current or recent (within the previous 6 weeks) infection or inflammation * Current or recent (within the previous 6 weeks) pressure ulcers or cutaneous lesions * Poorly controlled diabetes * An episode of AD in the previous 6 months that required medical intervention to resolve * Significant other neurological, psychiatric, pulmonary, cardiovascular, orthopaedic, or oncological conditions. * Currently taking part in another clinical trial * Upper limb contracture

Contact & Investigator

Central Contact

Laura Stendell

✉ laura.stendell@unimelb.edu.au

📞 (+61) 468 862 693

Principal Investigator

David Berlowitz, PhD

PRINCIPAL INVESTIGATOR

University of Melbourne

Frequently Asked Questions

Who can join the NCT06871254 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Spinal Cord Injuries. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06871254 currently recruiting?

Yes, NCT06871254 is actively recruiting participants. Contact the research team at laura.stendell@unimelb.edu.au for enrollment information.

Where is the NCT06871254 trial being conducted?

This trial is being conducted at Heidelberg, Australia.

Who is sponsoring the NCT06871254 clinical trial?

NCT06871254 is sponsored by University of Melbourne. The principal investigator is David Berlowitz, PhD at University of Melbourne. The trial plans to enroll 24 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology